Scientists probe bone marrow cells to unravel waldenström macroglobulinemia
NCT ID NCT07471074
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at bone marrow stem cells from 50 people with Waldenström macroglobulinemia, a rare blood cancer. Researchers want to see how these cells differ from healthy ones and how they might help the cancer grow. The goal is to better understand the disease, which could lead to new treatment ideas in the future.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could reveal how bone marrow stem cells support Waldenström macroglobulinemia, pointing toward new treatments that target the tumor's environment.
- What could go wrong
- This is an early observational study with only 50 participants, so findings may not apply broadly. It aims to understand the disease, not test a treatment, so direct patient benefits are unlikely soon.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with WM, meeting the diagnostic criteria defined at the 2nd WM Workshop, revised at the 9th international workshop. * Patients requiring treatment within 3 months according to the recommendations defined at the 2nd Workshop on WM. * Patients having given their consent for this study. * Affiliation to a social security scheme. Exclusion Criteria: * Patients with other chronic lymphoid hemopathies. Particular care should be taken to exclude other closely related lymphoplasmacytic proliferations, especially marginal zone lymphomas. * Patients with WM who have undergone histological transformation to a lymphoma other than diffuse large B- cell lymphoma. * Absence of consent for this study. * Patients under court protection, subjects participating in another study with an exclusion period still in progress at pre-inclusion.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Waldenström macroglobuloinemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHU Amiens
RECRUITINGAmiens, 80480, France